Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash from Financing Activities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Cash from Financing Activities for 3 consecutive years, with -$1.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash from Financing Activities rose 95.22% year-over-year to -$1.2 million, compared with a TTM value of -$52.0 million through Dec 2024, down 200.11%, and an annual FY2024 reading of -$52.0 million, down 200.11% over the prior year.
  • Cash from Financing Activities was -$1.2 million for Q4 2024 at Oramed Pharmaceuticals, up from -$1.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $74.5 million in Q3 2023 and bottomed at -$30.6 million in Q2 2024.
  • Average Cash from Financing Activities over 3 years is $974636.4, with a median of -$1000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities soared 1628.45% in 2023, then crashed 881.89% in 2024.
  • Year by year, Cash from Financing Activities stood at $4.2 million in 2022, then crashed by 698.8% to -$25.0 million in 2023, then skyrocketed by 95.22% to -$1.2 million in 2024.
  • Business Quant data shows Cash from Financing Activities for ORMP at -$1.2 million in Q4 2024, -$1.3 million in Q3 2024, and -$30.6 million in Q2 2024.